Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation.

In vivo (Athens, Greece) - 1 Jan 2000

Colombo Alfredo, Concetta Porretto Maria, Gebbia Vittorio, Sambataro Daniela, Scandurra Giuseppina, Valerio Maria Rosaria

Abstract excerpt

Patients affected by metastatic carcinoma of the colon/rectum (mCRC) harboring mutations in the BRAF gene (MBRAF) respond poorly to conventional therapy and have a prognosis worse than that of patients without mutations. Despite the promising outcomes of targeted therapy utilizing multi-targeted inhibition of the mitogen-activated protein kinase (MAPK) signaling system, the therapeutic efficacy, especially for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 39740863
DOI: 10.21873/invivo.13802

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation.PMID 39740863Read ↗

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkersSemantic proximity Read ↗

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Semantic proximity Read ↗

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.Semantic proximity Read ↗

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough ChallengeSemantic proximity Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review)Semantic proximity Read ↗

Emerging treatment options for BRAF-mutant colorectal cancerSemantic proximity Read ↗

Immunotherapy in Colorectal Cancer.Semantic proximity Read ↗

Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.